NasdaqCM - Nasdaq Real Time Price USD

GRI Bio, Inc. (GRI)

1.4400
-0.0600
(-4.00%)
As of 3:47:57 PM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for GRI

Recent News: GRI

View More
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
GlobeNewswire 3 days ago
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
GlobeNewswire 4 days ago
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire 11 days ago
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire 12 days ago
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference
GlobeNewswire last month
GRI Bio Announces Closing of $5.0 Million Public Offering

GRI Bio Announces Closing of $5.0 Million Public Offering
GlobeNewswire last month
GRI Bio Announces Pricing of $5.0 Million Public Offering

GRI Bio Announces Pricing of $5.0 Million Public Offering
GlobeNewswire last month
GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire last month
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
GlobeNewswire last month
GRI Bio Participates in a Virtual Investor CEO Connect Segment

GRI Bio Participates in a Virtual Investor CEO Connect Segment
GlobeNewswire 2 months ago
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire 2 months ago
View More

Related Tickers

BDRX Biodexa Pharmaceuticals Plc
1.2897
+0.76%
 
WINT Windtree Therapeutics, Inc.
0.7927
-4.26%
 
AEON AEON Biopharma, Inc.
0.5080
+1.60%
 
ELAB PMGC Holdings Inc.
2.5362
+2.68%
 
CDT Conduit Pharmaceuticals Inc.
0.3793
-2.74%
 
ADTX Aditxt, Inc.
1.7500
+5.42%
 
CERO CERo Therapeutics Holdings, Inc.
0.6027
+3.03%
 
ENTO Entero Therapeutics, Inc.
0.4108
-3.18%
 
REVB Revelation Biosciences, Inc.
3.1299
+2.62%
 
PTIX Protagenic Therapeutics, Inc.
11.54
+280.88%